Inhibitors and Activators of the p38 Mitogen- Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and Inflammation.

Denny, William A

dc.contributor.author	Denny, William A
dc.coverage.spatial	Netherlands
dc.date.accessioned	2022-06-12T23:04:25Z
dc.date.available	2022-06-12T23:04:25Z
dc.date.issued	2022-02-15
dc.identifier.citation	(2022). Current Cancer Drug Targets, 22(3), 209-220.
dc.identifier.issn	1568-0096
dc.identifier.uri	https://hdl.handle.net/2292/59738
dc.description.abstract	The p38 MAP kinases are a sub-family of the broad group of mitogen-activated serine-threonine protein kinases. The best-characterised, most widely expressed, and most targeted by drugs is p38α MAP kinase. This review briefly summarises the place of p38α MAP kinase in cellular signalling and discusses the structures and activity profiles of representative examples of the major classes of inhibitors and activators (both synthetic compounds and natural products) of this enzyme. Primary screening was primarily direct in vitro inhibition of isolated p38α enzyme.
dc.format.medium	Print-Electronic
dc.language	eng
dc.publisher	Bentham Science Publishers Ltd.
dc.relation.ispartofseries	Current cancer drug targets
dc.rights	Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.
dc.rights.uri	https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
dc.subject	Kinase
dc.subject	cancer
dc.subject	inflammation
dc.subject	inhibitors
dc.subject	p38MAPK
dc.subject	review
dc.subject	2.1 Biological and endogenous factors
dc.subject	5.1 Pharmaceuticals
dc.subject	0304 Medicinal and Biomolecular Chemistry
dc.subject	1112 Oncology and Carcinogenesis
dc.subject	1115 Pharmacology and Pharmaceutical Sciences
dc.title	Inhibitors and Activators of the p38 Mitogen- Activated MAP Kinase (MAPK) Family as Drugs to Treat Cancer and Inflammation.
dc.type	Journal Article
dc.identifier.doi	10.2174/1568009622666220215142837
pubs.issue	3
pubs.begin-page	209
pubs.volume	22
dc.date.updated	2022-05-19T23:29:00Z
dc.rights.holder	Copyright: The author	en
dc.identifier.pmid	35168519 (pubmed)
pubs.author-url	https://www.ncbi.nlm.nih.gov/pubmed/35168519
pubs.end-page	220
pubs.publication-status	Published
dc.rights.accessrights	http://purl.org/eprint/accessRights/RestrictedAccess	en
pubs.subtype	IM
pubs.subtype	Journal Article
pubs.elements-id	883324
pubs.org-id	Medical and Health Sciences
pubs.org-id	Science
pubs.org-id	Science Research
pubs.org-id	Medical Sciences
pubs.org-id	Auckland Cancer Research
pubs.org-id	Maurice Wilkins Centre (2010-2014)
dc.identifier.eissn	1873-5576
dc.identifier.pii	CCDT-EPUB-120903
pubs.record-created-at-source-date	2022-05-20